Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its lead product candidate, Selinexor , a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound, at the 56th American Society of Hematology Annual Meeting, held December 6-9, 2014 in San Francisco.
http://ift.tt/1z086tl
http://ift.tt/1z086tl
No comments:
Post a Comment